Kintara Therapeutics, Inc. NASDAQ: KTRA Company Profile, Contacts & Intelligence

Kintara Therapeutics, Inc. NASDAQ: KTRA Overview

Our Fight Against Cancer Kintara Therapeutics is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara Therapeutics has teamed up with outstanding academic and clinical research institutions from around the world to support the development of our novel cancer therapies. A Pipeline of Breakthrough Cancer Therapeutics VAL-083 is a first-in-class small molecule DNA-targeting agent that exhibits a novel mechanism of action that results in DNA double strand breaks and cancer cell death. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types. VAL-083's indications include: Glioblastoma Multiforme (GBM) Ovarian Cancer Pediatric CNS Tumors REM-001 is a second generation photosensitizer drug possessing multiple advantages over earlier generation PDT compounds. REM-001’s indications include: Cutaneous Metastatic Breast Cancer Recurrent Basal Cell Carcinoma Nevus Syndrome Hemodialysis Arteriovenous (AV) Access

Headquarters

12707 High Bluff Dr

Website

www.kintara.com

Industry

Biotechnology Research

Stock Symbol

KTRA

NAICS

Research and Development in Biotechnology (except Nanobiotechnology)

Kintara Therapeutics, Inc. NASDAQ: KTRA Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

Kintara Therapeutics, Inc. NASDAQ: KTRA People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

Kintara Therapeutics, Inc. NASDAQ: KTRA Workforce Composition

Seniority breakdown across 3 visible profiles.

Compare Similar Companies to Kintara Therapeutics, Inc. NASDAQ: KTRA

Explore companies in related markets and compare their industry and employee estimates.